A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta 1–42 Peptide in the Brain and Leads to Alzheimer’s Disease-Relevant Cognitive Changes in a Mouse Model

Abstract

Background:

Increased blood-brain barrier (BBB) permeability and amyloid-β (Aβ) peptides (especially Aβ_1–42) (Aβ₄₂) have been linked to Alzheimer’s disease (AD) pathogenesis, but the nature of their involvement in AD-related neuropathological changes leading to cognitive changes remains poorly understood.

Objective:

To test the hypothesis that chronic extravasation of bloodborne Aβ₄₂ peptide and brain-reactive autoantibodies and their entry into the brain parenchyma via a permeable BBB contribute to AD-related pathological changes and cognitive changes in a mouse model.

Methods:

The BBB was rendered chronically permeable through repeated injections of Pertussis toxin (PT), and soluble monomeric, fluorescein isothiocyanate (FITC)-labeled or unlabeled Aβ₄₂ was injected into the tail-vein of 10-month-old male CD1 mice at designated intervals spanning ∼3 months. Acquisition of learned behaviors and long-term retention were assessed via a battery of cognitive and behavioral tests and linked to neuropathological changes.

Results:

Mice injected with both PT and Aβ₄₂ demonstrated a preferential deficit in the capacity for long-term retention and an increased susceptibility to interference in selective attention compared to mice exposed to PT or saline only. Immunohistochemical analyses revealed increased BBB permeability and entry of bloodborne Aβ₄₂ and immunoglobulin G (IgG) into the brain parenchyma, selective neuronal binding of IgG and neuronal accumulation of Aβ₄₂ in animals injected with both PT and Aβ₄₂ compared to controls.

Conclusion:

Results highlight the potential synergistic role of BBB compromise and the influx of bloodborne Aβ₄₂ into the brain in both the initiation and progression of neuropathologic and cognitive changes associated with AD.

Keywords

Alzheimer’s disease amyloid-beta peptides amyloid plaques autoantibodies blood-brain barrier dementia immunoglobulin G

INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive destruction and loss of neurons and their synapses in the brain, gradually escalating cognitive decline and, ultimately, dementia and death [1 –6]. Currently, treatment options are limited and, at best, only temporarily alleviate some symptoms with no significant effect on disease progression [7 –9]. Seeking a better understanding of events and conditions that trigger and propagate AD pathogenesis is critical before effective disease-modifying therapies can be proposed and tested in clinical trials. Despite progress in our understanding of some key aspects of AD-related neuropathological and cognitive deficits, a complete picture of sequential stages during AD pathogenesis and its relationship with neuropsychological phenotypic outcome remains elusive [3, 5]. AD has been associated with a number of pathological features, including reactive gliosis, inflammation, and the appearance of hallmark amyloid plaques (APs) and neurofibrillary tangles (NFTs). These and other changes in the brain have been temporally and spatially linked to a progressive and severe decline in cognitive function [10 –12].

To identify potential early triggers of AD, determine its pathogenetic course, and ascertain which pathological features play a central role in driving the observed cognitive, memory and behavioral changes, much research has focused on APs, NFTs, neuroinflammation, and vascular pathology [13]. While the exact nature and magnitude of the contribution of each of these pathological features to disease progression continue to be debated, there is little doubt that the appearance of APs and NFTs in the brain parenchyma is directly linked to AD pathogenesis. It is generally thought that brain amyloid deposition in the form of APs precedes the appearance of NFTs [14 –18]. APs principally contain the amyloid-β_1–42 (Aβ₄₂) peptide, a self-assembling amyloidogenic peptide composed of 42 amino acid residues derived from cleavage of the amyloid-β protein precursor (AβPP) [19 –25]. Increased production of Aβ₄₂ and its deposition in the brains of patients with early onset, familial AD, as well as in certain transgenic mice, have confirmed correlations between Aβ₄₂ levels and the formation of APs, loss of synapses, and cognitive deficits [15 , 26–29]. Numerous studies have described Aβ₄₂ deposition in the form of APs and intraneuronal deposits, the latter primarily in the perikaryon of pyramidal cells in humans, transgenic rodents, and in vitro models [15 , 30–51]. Mechanisms associated with intraneuronal Aβ₄₂ deposition at each of these sites and their relationship to neuronal dysfunction and loss are being investigated [52, 53]. Determining the source(s) of the Aβ₄₂ peptide that eventually deposits within neurons and APs in the brain and the underlying reason for the requirement of advanced age remain key questions.

Aging-associated changes in the structural and functional integrity of blood vessels in the human brain have been extensively studied. Among these changes, a chronic increase in blood-brain barrier (BBB) permeability, resulting in a disruption of brain homeostasis, has long been suspected of playing a role in the triggering and/or progression of AD as well as in other neurodegenerative diseases, post-operative delirium, post-operative cognitive decline, Sundowner’s syndrome and the short- and long-term effects of traumatic brain injury [31 , 54–64]. There is some evidence that increased BBB permeability allows greater access of bloodborne Aβ peptides to neurons residing in the brain parenchyma [31]. Aβ peptides are detected in human blood and cerebrospinal fluid (CSF) [65 –70]. Since Aβ₄₂ peptide is detected in the blood (plasma) of both cognitively normal and AD subjects, it is not unreasonable to suspect that, in the context of BBB compromise and a prolonged pre-symptomatic phase, the blood could serve as a chronic source of the Aβ₄₂ peptide that is deposited in AD brains [31 , 65–70]. This scenario is supported by our earlier reports demonstrating the extravasation of various vascular components into the brain parenchyma in both AD and age-match non-demented controls [31, 71]. Our previous studies of human, porcine, rat and mouse brain have demonstrated a close spatial association between BBB leak sites and the locations of Aβ₄₂-burdened neurons [31 , 73]. For example, in a study on mice with an acutely compromised BBB, we tracked the fate of bloodborne, soluble Aβ₄₂ peptide and demonstrated that it readily entered the brain, was selectively bound to pyramidal neurons and was internalized by these cells, the same neuronal subtype that is typically overburdened with Aβ₄₂-rich deposits in human AD brains [31].

In the present study, we used the middle-aged (10 months old) mouse as a model system to investigate the long-term neuropathological effects of a chronically induced increase in BBB permeability and the resulting influx of soluble bloodborne fluorescein isothiocyanate (FITC)-labeled and unlabeled Aβ₄₂ into the brain parenchyma on the animals’ ability to learn (acquisition) and retain (long-term memory) information, as well as on selective attention. To induce chronic BBB dysfunction, Pertussis toxin (PT) was repeatedly injected into the tail vein of 10-month-old male CD1 mice for a little over three months. Mice also received tail vein injections of purified monomeric FITC-labeled or unlabeled Aβ₄₂ peptide at regular intervals over the same time period. During the last month of treatment, animals underwent a battery of cognitive and behavioral assessments. Mice injected with PT plus Aβ₄₂ demonstrated a deficit in long-term retention and increased susceptibility to interference in selective attention compared to controls exposed to either PT or saline only. Immunohistochemical analyses of brain samples revealed an increased influx of Aβ₄₂ and IgG into the brain parenchyma, selective neuronal binding of IgG, and intraneuronal accumulation of exogenous Aβ₄₂ in mice injected with PT plus Aβ₄₂ compared to controls. These findings highlight the potential contribution of an impaired BBB and the resulting influx of soluble, bloodborne Aβ₄₂ influx into the brain parenchyma in triggering the earliest cognitive and neuropathological changes associated with AD-related pathogenesis.

MATERIALS AND METHODS

Animals

All procedures involving animals were performed following the guidelines of the institutional animal care and use committee (IACUC) in accordance with NIH guidelines. Ten-month-old male CD-1 mice (Harlan) were randomly separated into three treatment groups: PT-Aβ₄₂ (n = 20) (animals injected with both PT and Aβ₄₂), saline (Sal) only controls (i.e., where PT and Aβ₄₂ injections were each replaced with saline) (n = 12), and PT-Sal controls (i.e., animals injected with PT but with Aβ₄₂ injections replaced with saline) (n = 12). Animals were acclimated to the laboratory for 14 days prior to the initiation of any treatments and were handled (held and manipulated by an experimenter) for 90 s/day during this period. This handling ensured that differential stress responses to the experimenters and any associated effects on learning were minimized. Animals were individually housed in clear boxes with floors lined with wood shavings in a humidity- and temperature-controlled vivarium adjacent to testing rooms. A 12/12-h light/dark cycle was maintained.

Preparation of Aβ₄₂ peptides and PT

Aβ peptides (FITC-Aβ₄₂, Anaspec, San Jose, CA; unlabeled Aβ peptides, Biosource, Camarillo, CA) were solubilized to the monomeric form according to the method described by Zagorski et al. (1999) [74]. Briefly, Aβ peptide was solubilized (1 mg/ml) in trifluoroacetic acid (TFA), followed by removal of TFA under a slow, steady stream of nitrogen gas. This was followed by three sequential solubilizations in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) followed by removal of HFIP under nitrogen gas each time. Stock solutions (50.0μM) were prepared in 0.5×PBS, 250.0 mM HEPES buffer (pH 8.5). Working solutions were diluted in 0.9% NaCl to 6.9μM and used for tail-vein injection. Peptide concentrations were confirmed using the Pierce Micro BCA Assay (Rockford, IL). Working solutions of PT (Sigma-Aldrich, St. Louis, MO) were diluted in 0.9% saline to 3.0 × 10⁻³ μg/μl prior to use in tail vein injection. Concentrations were confirmed using the Micro BCA Assay (Pierce; Rockford, IL).

Animal treatments

Tail vein injections of saline only (Sal), PT plus saline (PT-Sal), or PT plus Aβ₄₂ peptide (PT-Aβ₄₂) were administered according to the following time intervals and concentrations. To effectively achieve a permeable BBB, PT-Aβ₄₂ and PT-Sal mice were treated with PT (300 ng in 100μl 0.9% saline) for 3 months via tail vein injection, which has previously been shown to reliably induce increased BBB permeability in adult mice [31]. PT injections occurred on days 0, 3, 17, 33, 47, 61, and 75 of the 3-month injection period. To augment plasma levels of Aβ₄₂ in mice and track its fate, soluble Aβ₄₂ peptide was administered via tail vein injection (100 microliters of 6.9 micromolar in 0.9% saline) on days 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 42, 46, 49, 53, 56, 60, 63, 67, 70, 74, 77, 81, 84, 88, 91, and 95 during the same 3 month period. Given expected inherent levels of endogenous Aβ₄₂ peptide present in mice which, under conditions of increased BBB permeability, can also potentially enter the brain parenchyma, and to facilitate tracking the fate of tail vein-injected, bloodborne Aβ₄₂, a subset of PT-Aβ₄₂ treated mice (n = 12) were injected with FITC-labeled Aβ₄₂. In the remaining subset of PT-Aβ₄₂ mice (n = 8), animals were administered unlabeled Aβ₄₂ (U-Aβ₄₂) peptide to confirm observations with FITC-labeled Aβ₄₂ and to address the possibility that addition of the FITC moiety to the Aβ₄₂ peptide might somehow modify its behavior and/or fate in the animal. Controls for Aβ₄₂ and PT were injected with similar volumes of saline (100μl of 0.9% saline) with or without Aβ peptides following the same schedule described above. Following completion of one month of treatments, a battery of behavioral training and testing was initiated and continued for around five weeks post last injection on D-95.

Behavioral training and testing procedures

All animals were tested on five cognitive tasks (odor discrimination, passive avoidance, spatial water maze, Lashley Maze, and selective attention/disengagement) as described in detail previously (see the Supplementary Material for additional details) [75 –77]. These five tasks were chosen based on their suggested sensitivity to AD-related pathologies and/or their conceptual relevance to cognitive impairments associated with AD [78, 79]. Furthermore, while AD pathology is associated with learning impairments, tests of retention are sometimes more sensitive to mild or early impairments, and several of the tests employed here are amenable to tests of long-term retention [78]. The order in which tasks were administered was designed to separate tasks based on similar motivations, processes, or motor requirements (e.g., mazes of a similar nature, activity versus passivity) to minimize any potential transfer between tasks.

For the learning tasks requiring food deprivation, ad lib food was removed from the animals’ home cages at the end of the light cycle approximately 40 h prior to the start of training (and thus encompassing the “rest” day between successive tasks). During this deprivation period, animals were provided food in their home cages for 90 min/day during the last 2 h of the light cycle, and thus were approximately food-deprived for 16 h at the time of training or testing. To manage the large number of animals being tested, we split the animals into two batches and ran one behavioral test at a time. Each batch of animals included mice from all treatment groups. The sequential order of the behavioral tests run was as followed: Water Maze, Lashley’s III Maze, Passive Avoidance, Odor Discrimination, Water Maze Retention, Lashley’s III Maze Long-term, and Selective Attention.

Odor discrimination and choice

Rodents rapidly learn to use odors to guide appetitively reinforced behaviors [75]. Here, mice learned to navigate a square field in which unique odor-marked (e.g., almond, lemon, mint) food cups were in three corners. Although food was present in each cup, it was accessible in only one cup (e.g., that marked by a mint odor). Each animal was placed in the empty corner, after which it explored the field and eventually retrieved the single piece of available food. In subsequent trials, the location of the accessible food cup was changed, but was consistently marked by the mint odor. On successive trials, animals required less time to retrieve the food and made fewer approaches (i.e., “errors”) to food cups lacking food. In this task, poor learning performance is indicated by an increased number of errors (i.e., contacting a cup marked by an odor not associated with available food). Using this procedure, errorless performance is typically observed within 3–4 training trials.

One-trial passive avoidance

Animals learn to suppress movement to avoid contact with aversive stimuli [75]. This “passive avoidance” response is exemplified in “step-down” avoidance procedures, where commonly, an animal is placed on a platform, whereupon stepping off the platform it encounters an aversive stimulus [75]. Following only a single trial, animals are subsequently reluctant to step off a safe platform. In the present study, upon stepping off the platform, animals were exposed to a combination of bright light and a loud oscillating noise. The ratio of post-training to pre-training step-down latencies was calculated for each animal and served to index learning. It has been determined that asymptotic performance is apparent in group averages following 1–3 training trials; thus, performance after a single trial reflects (in most instances) sub-asymptotic learning and is sensitive to variations in the rate of learning between animals. Thus, higher Post/Pre-step-down latencies indicate better learning, i.e., acquired fear of leaving the safe platform.

Spatial Water Maze

For this task, animals are immersed in a round pool of opaque water from which they could escape onto a hidden (i.e., submerged) platform. The latency for animals to find the platform decreases across successive trials [80]. The performance of animals can improve across trials despite the animals beginning each trial from a new start location (i.e., efficient navigation requires the implementation of a “cognitive map”, rather than simply following a fixed route). Such a procedure mitigates against egocentric navigation (as could determine performance in the Lashley Maze) or fixed motor patterns and promotes the animals’ dependence on extra maze spatial landmarks and is said to reflect the animal’s representation of its environment as a “cognitive map”.

During training, shorter latencies to locate the escape platform across trials is indicative of more rapid acquisition of a stable cognitive map. To estimate capacity for long-term retention in this task, animals were tested with a “probe” trial following a 30-day retention interval from completion of acquisition training. On the probe test, the escape platform was removed from the pool, and all animals were started from the same start location. A 60-s test was conducted in which the animals’ time searching in the target quadrant (that in which the escape platform was previously located) and non-target quadrants were recorded. This measure served to index long-term retention in this task, i.e., an animal with good retention should spend significantly more time in the target quadrant (previous location of the escape platform) than non-target quadrants. Conversely, an animal with poor retention would not express any preference for the target quadrant.

Lashley III Maze

Mice can learn a pattern of egocentric navigation to locate food in a maze [75]. The Lashley III Maze consists of a start box, four interconnected alleys, and a goal box containing a food reward [75]. Over trials, the latency of rats to locate the goal box decreases, as do their errors (i.e., wrong turns or retracing). Here, mice were first acclimated to the Lashley Maze, then received five training trials during which errors were recorded. Using our parameters, mice reach asymptotic levels of performance (i.e., errors decrease to a stable level) in 4–6 training trials, thus five trials is sensitive to differences in rate of learning across animals. To estimate capacity for long-term retention in this task, following a 30-day retention interval from completion of training, animals were placed in the start box and allowed to traverse the maze again for two trials. To index the long-term retention using this task the difference between the first trial after the retention interval (T7) and the average of the last two trials in the acquisition period (T5 and T6) was used for each animal.

Selective attention/attentional disengagement

In the human Stroop Interference Test Condition, subjects are instructed to name the color of the ink that is used to spell a word rather than read the word. Subjects respond more quickly and make fewer errors when the written word and the color of ink are congruent (e.g., the word RED is spelled with red ink) relative to when the ink color and word disagree (e.g., the word RED is spelled with green ink). The increased latency and tendency to generate errors in the incongruent condition are believed to reflect a failure of selective attention, i.e., the subject is distracted from the task by the written word [81]. We have developed an analog of the Stroop Test for mice, wherein the attention directed toward an odor (or visual) cue is impaired when the animal is tested in the presence of a task-relevant visual (or odor) distractor [77, 82].

In the present task, mice were trained to perform an odor discrimination or a visual discrimination, each in a distinct context. In this manner, the context came to “instruct” the animal which discrimination to perform. After reaching asymptotic (near errorless) performance in each task, a test of selective attention was performed. For this test, the visual cues were added to the odor discrimination box. Given the previously learned instructions, the animal should ignore the visual cues and approach only the relevant odor cues. An increase in errors was deemed as a failure of the ability to selectively attend to the odor cues. After the completion of this test, the animals were subjected to a test of their capacity to disengage from the previous tendency to approach the odor cues. For this test, animals were placed in the visual discrimination box with both visual cues (the relevant targets) and odor cues (the task-relevant distracters) present. To perform effectively in the task, animals were required to inhibit their approach to recently reinforced odor cues and now attend only to visual cues to find food. Animals then alternated between boxes and were tested in this manner until they had been tested for performance in each box two times (for a total of four test trials). The number of errors accumulated over the test trials served as the index of selective attention and the animals’ ability to shift between relevant cues (i.e., to disengage from one type of cue and focus attention on the alternate type of cue). Errors were scored in the same manner described above for the Odor Discrimination task. A detailed description of this task is provided in the Supplementary Material.

Tissue preparation for neuropathological studies

Animals were euthanized at ∼14.5 months of age using pentobarbital (200 mg/kg) administered intraperitoneally. Brains were removed rapidly and fixed in 4% paraformaldehyde in PBS at 4°C for 7 days. From each animal brain, tissue blocks were generated for immunohistochemistry (IHC), including the cerebral cortex (from multiple locations), hippocampus and cerebellum. Following fixation, tissue was either paraffin-embedded or frozen. Paraffin-embedded tissues were sectioned at a thickness of 5.0μm, and sections were placed on Superfrost® Plus glass slides (48311-703, VWR, Bridgeport, NJ) previously coated with Poly-L-Lysine (P8920, Sigma-Aldrich, St. Louis, MO). Slides were baked at ∼60°C for 1 h to ensure tissue was fully adherent. Following fixation, tissue to be used for frozen sectioning was infiltrated with 10% and then 30% sucrose in PBS also containing 1.0% paraformaldehyde, pH 7.4) at 4°C under constant gentle agitation. Specimens were placed atop a solid 4.0% gelatin matrix and the resulting tissue/gelatin blocks were snap-frozen in liquid nitrogen and stored at −80°C. Cryosectioning was performed using a Leica CM1850 Cryostat (Deerfield, IL). Cryosections (12.0μm thick) were placed on Superfrost® Plus glass slides and stored in a dry container at 4°C until use.

Brightfield immunohistochemistry

Paraffin-embedded tissues were processed for brightfield IHC as described previously [30 , 84]. Briefly, after removal of paraffin with xylene and rehydration through a graded series of decreasing concentrations of ethanol, protein antigenicity was enhanced by microwaving sections in Target Buffer (Dako, Carpenturia, CA) for 2 min. Following a 30-min incubation in 0.3% H₂O₂, sections were treated for 30 min in normal blocking serum and then incubated with primary antibodies (anti-Aβ₄₂ antibodies polyclonal, 1:50 dilution, AB5078P, Chemicon International, Temecula, CA; anti-mouse IgG, dilution 1:100, Millipore, Temecula, CA) for 1 h at room temperature. After a thorough rinse in PBS, a secondary biotin-labeled antibody was applied for 30 min at room temperature. Immunoreactions were treated with the avidin–peroxidase-labeled biotin complex (ABC, Vector Labs, Foster City, CA) and visualized with 3-3-diaminobenzidine-4 HCl (DAB)/H₂O₂ (Biomeda, Foster City, CA). Sections were lightly counterstained with hematoxylin, dehydrated using increasing concentrations of ethanol, cleared in xylene and mounted in Permount. The specificity of immunoreactivity was confirmed by incorporating various antibody controls during each IHC run. Since the specificity of anti-Aβ₄₂ antibodies are controversial, we used one of the most widely used and tested anti-Aβ₄₂ antibodies. All specimens were examined and photographed with a Nikon FXA microscope, and digital images were recorded using a Nikon DXM1200F digital camera and processed using Image Pro Plus (Phase 3 Imaging, Glen Mills, PA) imaging software.

Fluorescent imaging

A subset of frozen brain sections from mice treated with PT and FITC-labeled Aβ₄₂ were washed in PBS, mounted using 4,6-diamidino-2-phenylindole, or DAPI (H-1500, Vector Laboratories, Burlingame, CA), and examined via fluorescence microscopy to assess the localization of FITC-conjugated peptides.

Counting the number of IgG or Aβ₄₂ positive neurons

The number of Aβ₄₂-positive cells was determined from sections of brain tissue from four animals in each of the treatment groups. Sections of paraffin-embedded tissue were immunostained with anti-Aβ₄₂ antibodies under identical conditions. Five random images at 20X magnification from each animals’ cortical region were recorded under identical illumination, magnification and camera settings using a Nikon FXA microscope equipped with a Nikon CCD camera. Similarly, Aβ₄₂-positive cells were visualized in the five random images at 20X magnification of the frozen brain cortical region using fluorescence settings of Nikon FXA microscope and Nikon Immunofluorescence camera. The total number of Aβ₄₂-positive cells in each 20X viewing field was counted. Various statistical tools were used to test the significance of differences among the different treatment groups.

Statistical analyses

After data collection, descriptive statistics for each group was examined along with the normality of the distribution. Multiple tests were used to ensure that the data followed a normal distribution, in which case an ANOVA analysis was carried out. A mixed effects analysis was preferred when there were missing data points in animal behavioral studies. If the distribution pattern of the acquired data were not normal, unpaired, non-parametric Mann-Whitney t-tests were carried out. Analyses were carried out using SPSS (v28) and GraphPad Prism (v10) while GraphPad Prism (v10) was used to generate graphs.

RESULTS

Overall, on several cognitive tasks and acquisition tests, mice treated with PT plus Aβ₄₂ (PT-Aβ₄₂) showed deficits compared to mice treated with PT plus saline (in place of Aβ₄₂) (PT-Sal) or saline only (Sal). By contrast, in most tests, PT-Sal mice generally did not exhibit decrements in performance compared to Sal mice. A similar pattern was observed in tests of long-term retention, where PT-Aβ₄₂ mice demonstrated a marked inability to recall trained activities relative to PT-Sal and Sal mice. Results from specific tests are described below.

Odor discrimination

No significant difference in the number of errors was observed between groups in Trial 1 (before learning could have occurred; Fig. 1A). However, closer inspection of the acquisition curves suggests that the rate of acquisition was slower in PT-Aβ₄₂ mice relative to the other groups, an effect that became increasingly apparent as trials progressed. This pattern was reflected in a significantly greater number of errors (p < 0.01) in the final two trials (Trials 4 and 5) for PT-Sal and Sal mice. These observations suggest a specific deficit in the rate of acquisition in the PT-Aβ₄₂ group.

Fig. 1

Mice treated with PT-Aβ42 (PT-Aβ₄₂) showed deficits compared to PT-Sal and Sal-only mice. A) Odor Discrimination. Animals were trained to locate food in randomly assorted locations by using an odor cue. Mean errors to locate the target food cup for animals in each treatment group are shown. Brackets indicate standard error. Using a mixed effects analysis, we did not find any significant difference between the treatment groups across trials 1 through 3; however, when trials 4 and 5 were compared, a statistically significant difference (p < 0.01) was observed in the PT-Aβ₄₂-treated mice compared to the other groups. B) Passive Avoidance: Post/Pre-Latency(s). Upon stepping from a safe platform, animals were exposed to a bright light, loud noise, and vibration. The mean ratio of post-training to pre-training step-down latencies was calculated for each animal and served to index learning. Brackets indicate standard errors, and the values were analyzed using the Mann-Whitney test. Animals treated with PT-Aβ₄₂ showed a significantly lower step-down latency compared to the Sal group (PT-Sal, p < 0.01). Likewise, the PT-Aβ₄₂ group demonstrated significantly lower step-down latency compared to PT-Sal group (p < 0.01). The PT-Sal and Sal-only groups failed to demonstrate any significant differences.

Passive avoidance: post/pre-latency(s)

PT-Aβ₄₂ mice exhibited inferior performance on the passive avoidance task, but this difference did not achieve statistical significance in the overall ANOVA (Fig. 1B). However, comparisons between the PT-Aβ₄₂ and Sal groups or the PT-Aβ₄₂ and PT-Sal groups indicated that the performance of the PT-Aβ₄₂-treated group was significantly worse than in animals treated with PT-Sal or Sal as these comparisons reached statistical significance (p < 0.01) (Fig. 1B). On the contrary, paired comparison between mice treated with PT-Sal and Sal were not statistically different from each other (Fig. 1B).

Spatial Water Maze

We investigated the animals’ ability to learn a task (spatial navigation, Fig. 2A) and retain over a long retention interval (Fig. 2B) the learned response for all treatment groups. All groups were found to exhibit equivalent performance in their ability to learn the task across trials, i.e., the groups did not differ in their rate of acquisition (Fig. 2A). The latency to locate a submerged platform gradually declined in later trials (Fig. 2A), suggesting that PT-Aβ₄₂ mice also learned spatial navigation at a normal rate (Fig. 2A). On mixed effect analysis, we observed statistical difference between the trials (p < 0.0001) without any difference between three treatment groups in each trial (Fig. 2A).

Fig. 2

A) Spatial Water Maze: Latency to Locate Platform. Animals were trained to locate a hidden platform submerged below the surface in a tank of water. The latency to locate the hidden platform was recorded across each of 12 training trials for animals in each treatment group. Brackets indicate standard error. The mice in all treatment groups demonstrated steady progress in locating submerged platform as revealed by the declined period from first to twelfth trial. Mice in all treatment groups also demonstrated comparable abilities to learn a task. B) Spatial Water Maze Retention: Percent Time(s) in Target Quadrant. Following a 30-day retention interval, animals were administered a 60-s “probe” trial in which the escape platform was removed from the maze and the percentage of time spent searching in the target quadrant was recorded. Mean time in the target quadrant is depicted. Brackets indicate standard error. For comparison across the three treatment groups, we used the Brown-Forsythe ANOVA test and found significant difference (p < 0.05) across the treatment groups. Overall, the PT-Aβ₄₂ group spent less time in the target quadrant compared to both PT-Sal and Sal groups. C) Lashley Maze: Errors to Complete: Long-term Retention. Mice were trained to locate food in the Lashley Maze over 6 trials (T1–T6) and re-tested on 2 trials (T7–T8) following a 30-day retention interval. Mean errors to reach the goal box across trials are depicted for each treatment group. Brackets indicate standard error. As the training progressed, T1–T6, the number of errors was consistently reduced for mice treated with PT-Sal and Sal. Sal and PT-Aβ₄₂ groups demonstrated inconsistent results as their number of errors fluctuated considerably. At T7, PT-Aβ₄₂ mice demonstrated a significant increase in errors compared to both PT-Sal and Sal groups. The number of errors made by mice from the PT-Aβ₄₂ group at T7 was higher than during T1. The number of errors made by mice in the PT-Sal and Sal groups at T7 was similar and lower than T1. D) A measure of retention was computed for each animal by obtaining a difference score between the errors committed on the first post-time lapse trial (i.e., T7) and the average of the last two acquisition trials (T5–6). Brackets indicate standard error. A comparison of the errors between the Sal and PT-Aβ₄₂ groups attained statistical significance (*p = 0.0409). Interestingly, between the PT-Aβ₄₂ and PT-Sal groups, the PT-Aβ₄₂ group demonstrated more errors and the numbers approached a similar trend (^#p = 0.0571).

Thirty days after completion of training, the same mice were tested for long-term retention of the learned response in the Spatial Water Maze. Mice treated with PT-Aβ₄₂ exhibited significant impairments of long-term retention relative to the other groups. This difference reached statistical significance in the overall Brown-Forsythe ANOVA (p < 0.05) (Fig. 2B). Paired comparison between PT-Aβ₄₂-treated mice to PT-Sal mice as well as PT-Aβ₄₂-treated mice to Sal mice demonstrated a reduced tendency in PT-Aβ₄₂-treated mice to retain the learned task (Fig. 2B). This pattern is particularly notable given the intact acquisition observed on this task in PT-Aβ₄₂-treated animals (Fig. 2A).

Lashley III Maze

In the Lashley III Maze, PT-Aβ₄₂-treated mice learned how to navigate the maze in a manner comparable to mice in the other groups, as overall rates of acquisition were largely similar in this task (Fig. 2 C). These values did not reflect the subjects’ failure to learn, as they were evident on the first trial prior to any learning having occurred. As in the Spatial Water Maze, mice were tested for long-term retention in the Lashley III Maze at a 30-day interval. In contrast to their varying pattern of performance on tasks assessing acquisition abilities, mice treated with PT-Aβ₄₂ again exhibited a performance deficit compared to the other groups (Fig. 2D). This impaired retention in PT-Aβ₄₂ animals reached significance relative to mice in the Sal group (p < 0.05, Fig. 2D). A similar trend of difference in this regard was noted between the PT-Sal and Sal groups (p = 0.0571, Fig. 2D). Interestingly, paired comparison between the PT-Aβ₄₂-treated and PT-Sal-treated groups failed to attain statistical significance (Fig. 2D). Most importantly, the observed decline in retention in PT-Aβ₄₂ animals was especially notable in the context of the fact that animals in all groups demonstrated comparable acquisition rates during initial training on this task (Trials 1–6, Fig. 2C).

Selective attention

The selective attention task is a test that is distinct from the other cognitive tasks used here. It occurs after asymptotic acquisition and makes no nominal demands on learning or long-term retention. On this test, a severe deficit was expressed by PT-Aβ₄₂ mice relative to all other groups as determined by a trials×Group interaction (p < 0.001, Fig. 3). This deficiency appeared to be related to an interference effect that likely accumulated across successive trials given its specific emergence on later trials when the odor cue served as the task-relevant distractor (after previously serving as the target cue; Fig. 1A). This was evidenced by significant increases in errors relative to each other group on trials 5–7, as determined by planned comparisons (p < 0.05, Fig. 3). This pattern of results suggests that PT-Aβ₄₂ mice were cognitively “rigid” and could not adapt to the changing conditions required for effective directed attention (i.e., when odor cues changed from target to distractor).

Fig. 3

Selective Attention/Disengagement is reduced in mice treated with PT-A β₄₂. Animals were trained on both odor and visual discriminations, each in a distinct context. On Trials 1- to 4, mice were tested on odor discrimination with visual discrimination cues present as distractors. All groups performed similarly on these tests. On Trials 5–8, mice were tested either on the visual discrimination with odor distractor cues present (Trials 5–V & 7-V), or on the odor discrimination with visual distractor cues present (Trials 6 & 8). PT-Aβ₄₂ mice demonstrated increased errors and performed poorly relative to the PT-Sal and Sal groups. Significant differences between PT-Aβ₄₂ and the other two groups are noted. These results indicated that PT-Aβ₄₂ mice could not disengage from a previously reinforced cue, indicative of a failure of selective attention (*p < 0.05).

Repetitive Pertussis toxin (PT) treatments facilitate chronic compromise of BBB integrity and leak of plasma components, including IgG antibodies, into the cerebral cortex

To chronically increase BBB permeability in mice, PT was repeatedly injected (seven times over three months) into the tail vein as described previously [31]. Leak of IgG from the brain vasculature was used as a marker of PT-induced BBB breach in the cerebral cortex and hippocampus (Fig. 4A–D). Such leaks were observed in all PT-treated mice. Interestingly, IgG leaks did not occur uniformly along the length of brain blood vessels, but rather were variable in location and extent, and were not limited to blood vessels of a single hierarchical type. Leaks ranged from small focal plumes of material emerging from a single site (Fig. 4A, B) to more extensive leaks occurring along a greater length of the vessel and its tributaries. In general, larger vessels (especially arterioles) displayed more extensive perivascular leak clouds than smaller vessels. Areas lacking discernible leaks often exhibited a sharp interface between IgG-positive and -negative regions (Fig. 4C, D). By contrast, IgG was mostly confined to the brain vasculature in Sal mice (Fig. 4E). Thus, repetitive PT treatments facilitate chronic compromise of BBB integrity and leak of plasma components, including IgG antibodies, into the cerebral cortex.

Fig. 4

PT induces leak of plasma components and selective binding of IgG to local neurons . A–D) Histological sections from the mouse cerebral cortex (Ctx) showing the effects of long-term PT treatment on BBB permeability. BBB leak was revealed as increased IgG immunoreactivity either widespread throughout the parenchyma or as more focused perivascular leak clouds (enclosed by dashed circles), with sharp interfaces (C, D) of IgG immunoreactivity often observed. IgG-immunopositive neurons were present within or in the vicinity of leak clouds (A, C, D). Neurons positioned more remotely from the leak showed little or no IgG labeling (black arrowheads, A–C). D) PT-Aβ₄₂ mice showed the most prominent IgG leaks and most extensive labeling of the neurons. The pyramidal neurons (PNs) outside of leak zones failed to demonstrate IgG immunoreactivity (black arrowheads). E) In the Sal-only group, IgG immunoreactivity was mostly localized within the blood vessels. F) Comparison between Sal-only and PT-Sal and Sal-only and PT-Aβ₄₂ attained statistical significance (Mann-Whitney test, p < 0.0001). Though the PT-Aβ₄₂ group demonstrated a higher number of PNs demonstrating IgG immunoreactivity compared to the PT-Sal group, it failed to attain statistical significance (Mann-Whitney test). Error bars indicate standard error of the mean (SEM). BV, blood vessel; Cap, capillary; Ctx, cerebral cortex. Scale bar = 50μm.

Chronically increased BBB permeability allows IgG antibodies to enter the brain parenchyma and bind selectively to neurons, especially pyramidal cells in the cerebral cortex

IgG entering the brain interstitial space was found to bind preferentially to certain neuronal subtypes, especially pyramidal neurons positioned within or near perivascular leak clouds (Fig. 4A–D). The intensity of neuronal IgG immunoreactivity decreased rapidly with increasing distance from the vessel leak site, often forming a well-defined leak interface (Fig. 4A–D). While increased permeability of the BBB to IgG was evident in the cerebral cortex of PT-Aβ₄₂ and PT-Sal mice relative to Sal controls, vascular leaks were most prevalent in the brains of PT-Aβ₄₂ mice, leading to an increased cortical density of IgG-positive neurons (Fig. 4D, F). In contrast to PT-Aβ₄₂ and PT-Sal animals, Sal animals exhibited a generally intact BBB within the cortex (Fig. 4E, F). We also found a significant difference in the density of IgG-positive cortical neurons across treatment groups (Fig. 4F). Paired comparison between the PT-Sal and Sal groups reached statistical significance, as did comparison of Sal mice with PT-Aβ₄₂ mice (p < 0.0001) (Fig. 4F). Although we observed a greater density of IgG-positive cortical neurons in PT-Aβ₄₂ mice compared to PT-Sal mice, this difference failed to achieve statistical significance (Fig. 4F).

Chronic BBB compromise allows bloodborne Aβ₄₂ to enter the brain parenchyma and accumulate within neurons in the cerebral cortex

The fate of exogenous Aβ₄₂ in animals with and without chronic PT-induced BBB compromise was tracked over a three-month period (final age ∼14.5 months) using FITC-labeled Aβ₄₂ peptide administered via tail vein injection. A group of PT-injected mice also received FITC-Aβ₄₂ injections throughout this period (26 times over 95 days), and the fluorescent signal was used to localize FITC-Aβ₄₂ in tissue sections of the cerebral cortex (Fig. 5). In regions exhibiting vascular leak, FITC-Aβ₄₂ was observed emerging from the walls of blood vessels and entering the surrounding brain interstitial space (Fig. 5A). Many (but not all) neurons within or in the vicinity of perivascular leak clouds exhibited intense FITC-Aβ₄₂ fluorescence in their cytoplasm, but not in nuclei, indicating a selective affinity of exogenous FITC-Aβ₄₂ for these neurons and its localization in the cytoplasmic compartment (Fig. 5A–D). As for IgG, neurons showing the greatest intensity of neuronal FITC-Aβ₄₂-positive fluorescence were those positioned closest to the source vessel (Fig. 5A, B). FITC-Aβ₄₂ was also localized within numerous discrete granules in neuronal perikarya, suggesting that exogenous, cell surface-bound FITC-Aβ₄₂ can be internalized and most likely makes its way into elements of the lysosomal compartment (Fig. 5C, D). Intraneuronal deposition of FITC-labeled Aβ₄₂ was clearly selective for certain types of neurons, especially pyramidal cells (Fig. 5A), with the most prominent labeling associated with larger pyramidal neurons that populate the lower layers of the cerebral cortex. Interestingly, great variations in the relative content of intracellular Aβ₄₂ were observed among neurons (e.g., compare Fig. 5A–D). FITC-Aβ₄₂-positive neurons were lacking in the cerebral cortex of PT-Sal and Sal mice (Fig. 5E, F).

Fig. 5

FITC-labeled A β₄₂ enters the brain parenchyma, shows selective affinity for pyramidal neurons, and is internalized within these cells. A–D) In the cerebral cortex of mice injected with PT and FITC-Aβ₄₂, FITC-Aβ₄₂ leaks out from blood vessels (white dashed circle in A) and is selectively internalized in pyramidal neurons (B–D). In neurons, FITC-Aβ₄₂ was localized within numerous discrete granules in the neuronal perikaryon, suggesting that cell surface-bound FITC-Aβ₄₂ is internalized and accumulates within a membrane-enclosed compartment. E, F) Background fluorescence in the cerebral cortex of mice not exposed to FITC-Aβ42 [i.e., PT-Sal (E) and Sal-only (F)] mice. No punctate immunofluorescence like FITC-Aβ₄₂ was seen in PT-Sal (E) and Sal-only (F) mice. PN, Pyramidal neurons: BV, blood vessel; Cap, capillary; PT, Pertussis toxin; Ctx, cerebral cortex. Scale bar = 50μm.

In PT-treated animals injected with unlabeled Aβ₄₂ (U-Aβ₄₂) peptide instead of the FITC-labeled peptide, the distribution of U-Aβ₄₂ in the brain following the long-term treatment course was investigated by bright field immunohistochemistry (red arrows, Fig. 6A, B). As expected, PT-U-Aβ₄₂ treated mice demonstrated a U-Aβ₄₂ distribution of pattern within the brain parenchyma that closely resembled that of FITC-Aβ₄₂-injected animals (red arrows, Fig. 6A, B). Controls injected with saline in place of U-Aβ₄₂ showed no detectable U-Aβ₄₂ in the brain parenchyma (Fig. 6C). Interestingly, PT-Sal mice (not injected with U-Aβ₄₂) also showed increased intraneuronal Aβ₄₂, although less than that of PT-U-Aβ₄₂ treated mice, suggesting that endogenous mouse Aβ₄₂ is also able to enter the brain parenchyma via a compromised BBB and preferentially associate and accumulate within local neurons (Fig. 6D).

Fig. 6

Cortical pyramidal neurons in mice treated with PT + unlabeled A β₄₂ (U-Aβ₄₂) peptide showed an increase in intraneuronal A β₄₂ accumulation comparable to that seen in mice treated with PT+FITC-labeled Aβ₄₂ (FITC-Aβ₄₂) peptide. Bright-field immunohistochemistry with anti-Aβ₄₂ primary antibody was used to compare the fates of injected U-Aβ₄₂ and FITC-Aβ₄₂ in the context of PT-induced chronic BBB breakdown. A, B) Both PT + U-Aβ₄₂- and PT + FITC-Aβ₄₂-treated mice demonstrated increased neuronal accumulation of Aβ₄₂ in the cerebral cortex (Ctx), red arrows. C) No evidence of neuronal Aβ₄₂ deposition was observed in Sal-only mice. D) Mice in the PT-Sal group also demonstrated some intraneuronal Aβ₄₂, but this was much less extensive and was often largely confined to small, isolated groups of neurons. This suggests that soluble, endogenous mouse Aβ₄₂ is also able to enter the brain parenchyma through a defective BBB. It is important to point out that, using the bright field microscopy, we are unable to differentiate between endogenous Aβ₄₂ peptides from the FITC-Aβ₄₂ peptide. PN, pyramidal neuron; BV, blood vessel; Cap, capillary; PT, Pertussis toxin; Sal, saline. Scale bar = 50μm.

BBB compromise increases the density of Aβ₄₂-positive neurons

We measured the density of Aβ₄₂-positive neurons (those exhibiting surface-bound and/or intracellular Aβ₄₂) in sections of the mouse cerebral cortex processed for detection of FITC-Aβ₄₂ using fluorescence microscopy (Fig. 7A) or U-Aβ₄₂ using Brightfield IHC and purified anti-Aβ₄₂ antibodies (Fig. 7B). Fluorescence data demonstrated a significantly higher density of FITC-Aβ₄₂-positive neurons in mice injected with PT plus FITC-labeled Aβ₄₂ (p < 0.0001) compared to Sal and PT-Sal groups (Fig. 7A). Similarly, mice exposed to PT plus U-Aβ₄₂ showed an increased density of U-Aβ₄₂-positive neurons within the cortex relative to PT-Sal (p < 0.01) and Sal (p < 0.0001) mice, (Fig. 7B). Brightfield IHC also showed a significantly higher number of Aβ₄₂-positive neurons in the PT-Sal group compared to the Sal group (p < 0.001) (Fig. 7B).

Fig. 7

The density of A β₄₂ positive neurons in the cerebral cortex was highest in PT-A β₄₂ mice. A) A comparison of the density of Aβ₄₂-positive neurons in mice injected with FITC-Aβ₄₂ peptide was carried out by immunofluorescent microscopy. A difference in the density of Aβ₄₂-positive neurons in the cerebral cortex was detected across the three treatment groups. Comparison of the density of Aβ₄₂-positive neurons reached statistical significance (Mann-Whitney tests, p < 0.0001) between the Sal-only and PT-FITC-Aβ₄₂ groups. The difference in the density of Aβ₄₂-positive neurons also reached statistical significance (Mann-Whitney tests, p < 0.0001) between the PT-Sal and PT-FITC-Aβ₄₂ groups. B) Comparison of the density of Aβ₄₂-positive neurons reached statistical significance (Mann-Whitney tests, p < 0.0001) between the Sal-only and PT-Aβ₄₂ groups. Similarly, group comparisons between Sal and PT-Sal, and PT-Sal and PT-Aβ₄₂ groups also attained statistical significance (Mann-Whitney tests, p < 0.001 and p < 0.01, respectively). Error bars are standard error of the mean (SEM).

Accumulation of bloodborne Aβ₄₂ within hippocampal hilar neurons

In PT-FITC-Aβ₄₂-treated animals, the hippocampus also showed blood vessels with prominent perivascular IgG-positive leak clouds extending out into the hippocampal parenchyma (Fig. 8A, D), which were not seen in PT-Sal mice (Fig. 8B, E) and Sal mice (Fig. 8C, F). As in the cerebral cortex, larger vessels in the hippocampus displayed the most extensive leak clouds (Fig. 8A). In mice injected with PT-FITC-Aβ₄₂, the fate of FITC-Aβ₄₂ in the hippocampus mirrored that in the cerebral cortex. A considerable number of the large hilar neurons exhibited intense FITC-Aβ₄₂ fluorescence localized within discrete granules in the neuronal perikaryon, again suggesting that exogenous FITC-Aβ₄₂ is selectively internalized by these neurons and most likely deposited within elements of the lysosomal compartment (Fig. 8D). No fluorescent signal similar to that from FITC-Aβ₄₂ was seen in hippocampal neurons of animals PT-Sal and Sal control animals (Fig. 8E, F).

Fig. 8

The hippocampal region of PT -A β₄₂ mice also showed increased BBB breakdown and intraneuronal accumulation of FITC-A β₄₂. A–C) Representative images from paraffin-embedded sections through the hippocampal region of PT-Aβ₄₂ mice showing extensive BBB leak of IgG compared to PT-only and Sal-only groups. D) Representative images from PT-FITC-Aβ₄₂-treated mice demonstrating intraneuronal accumulation of FITC-Aβ₄₂ in hippocampal hilar neurons. E, F) The hippocampal region of the PT-Sal and Sal-only mice lacked FITC-positive fluorescence. Hippo, hippocampus; BV, blood vessel; Cap, capillary. Scale bar = 50μm.

DISCUSSION

The goal of the present study was to use an aging mouse model to investigate the effects of long-term, chronic BBB compromise on the fate of exogenous bloodborne Aβ₄₂ peptide and cognitive function. To achieve this, 10-month-old mice were treated repeatedly with Pertussis toxin (PT) to induce a chronic increase in BBB permeability over a period of three months. During the same interval, animals were also repeatedly administered purified FITC-labeled or unlabeled Aβ₄₂ via tail vein injection. Controls were similarly injected with PT plus saline or saline only. FITC-labeled Aβ₄₂ was used to track the fate of bloodborne Aβ₄₂ in the brain tissue. During the last month of treatment, all mice underwent extensive behavioral testing. Animals were subjected to a wide range of learning, attentional, and long-term retention tests that relied on diverse motivational and neural systems. Following completion of behavioral testing, animals were sacrificed, and the brains removed and evaluated to determine the distribution of tail vein injected Aβ₄₂ peptide (FITC-labeled and unlabeled) and bloodborne IgG, both of which are normally blocked from entry into the brain in animals with a functionally intact BBB.

This study had four main findings. First, repetitive PT treatments induced a chronic increase in BBB permeability, leading to an influx of plasma components into the brain parenchyma, including IgG antibodies and FITC-labeled and unlabeled Aβ₄₂ peptide. BBB leaks were evident as IgG- and Aβ₄₂-positive perivascular leak clouds in PT-treated mice and were most prominent in mice treated with PT plus Aβ₄₂. Second, after entering the brain parenchyma, both IgG and Aβ₄₂ preferentially associated with certain types of neurons, mostly pyramidal neurons in the cerebral cortex and the large hilar neurons in the hippocampus. In these neurons, internalized FITC-labeled Aβ₄₂ was most often localized within discrete cytoplasmic granules, presumably structures associated with the neuronal lysosomal compartment. We also found that endogenous Aβ₄₂ was detectable in neurons in PT-treated mice (PT-Saline Control), but not in mice injected with saline-only (Saline-Saline Control), suggesting that disruption of the BBB in mice is required for entry of bloodborne Aβ₄₂ into brain. Third, chronic BBB compromise increased the density of Aβ₄₂-positive neurons and thus total brain Aβ₄₂ load in animals injected with Aβ₄₂ via the tail vein. Cells containing the greatest amounts of Aβ₄₂ were positioned either within or in the vicinity of the leak, but no Aβ₄₂-immunopositive amyloid plaques were found in any treatment group. Fourth, with respect to cognitive functioning, animals with chronic BBB compromise and injected Aβ₄₂ displayed a pattern of variable disruption of the acquisition of learned behaviors, a more consistent and preferential deficit in the capacity for long-term retention, and increased susceptibility to interference in selective attention. Taken together, these results indicate that chronic disruption of the BBB and the resulting influx of exogenous Aβ₄₂ and neuron-binding IgG antibodies (autoantibodies) from the blood into the brain in mice can mimic pathological events associated with early AD-related pathology in humans as well as cause comparable early changes in behavior and cognition. In addition, our data supports the notion that blood is a likely source of exogenous Aβ₄₂ peptide that eventually deposits in the brains of people afflicted with AD, with autoantibody-induced endocytosis as a route of Aβ₄₂ entry into neurons.

BBB compromise and AD

Results of the present study are in accord with previous work suggesting that cerebrovascular changes are key contributors to early AD pathogenesis and subsequent disease progression [31 , 85–93]. Studies on humans and animal models have suggested that long-term, functional compromise of the BBB may contribute to initiation and/or progression of AD pathology, although the exact nature of its contribution is yet to be defined [30 , 85–93]. Despite this, it is reasonable to expect that long-term increase in BBB permeability result in a chronic, gradually escalating disruption of brain homeostasis due to the influx of plasma components, including immunoglobulins (Igs) and Aβ peptides, into the brain [30 , 92]. For obvious reasons, studies on the causal mechanisms of BBB compromise and long-term consequences in humans have been limited, necessitating the use of animal models. A missing feature that weakens the utility of mouse models for studies on the potential role of BBB compromise in AD pathogenesis is that, unlike in humans, mice lack comparable aging-associated changes in the structural/functional integrity of brain blood vessels, including those thought to lead to chronically increased BBB permeability in humans, and apparently do not live long enough to allow the full extent of AD-related pathological changes to evolve. In a previous study, we examined the fate of FITC-labeled Aβ₄₂ that was introduced into mice via a single bolus tail vein injection, with the BBB rendered permeable by a single treatment with PT [31]. This study showed that FITC-Aβ₄₂ readily penetrated the BBB and was localized in neurons. To test the requirement for disruption of the BBB to allow the influx of bloodborne FITC-Aβ₄₂ into the brain tissue, mice were subjected to saline injections in place of PT prior to administration of FITC-Aβ₄₂ by tail vein injection. Results showed that FITC-Aβ₄₂ was detected in the brain but was confined to the lumen of blood vessels, and neurons throughout the brain were devoid of FITC-Aβ₄₂ [31]. In the present study, we induced a chronic, increase in BBB permeability in mice via repetitive PT injections over a period of three-months, an approach confirmed to be successful by demonstrating a resulting influx of bloodborne IgG and FITC-labeled and unlabeled Aβ₄₂ into the brain parenchyma. Although PT has been widely used in developing various animal models with impaired BBB, details on how PT mediates the observed increase in BBB permeability remains poorly understood [94]. The observation of rather sharp interfaces between IgG- and Aβ₄₂-positive and -negative brain regions in these mice indicated that the site and extent of BBB compromise was not uniform in the cerebral cortex or hippocampus. A similar phenomenon has been reported in postmortem AD brains [30, 31], providing a plausible explanation for the often unpredictable pattern of symptoms that emerge early in the course of the disease, which later become more generalized as the disease progresses.

Bloodborne IgG and Aβ₄₂ preferentially associate with pyramidal neurons

The present study shows that a chronic BBB compromise allows bloodborne IgG antibodies and FITC-labeled Aβ₄₂ to gain access to neurons and glial within the brain parenchyma, suggesting that the blood can serve as a major source of the Aβ₄₂ peptide that accumulates in AD brains under conditions of increased BBB permeability. Indeed, several studies have suggested that the blood can serve as a source of Aβ peptides that deposit in the brain of AD patients [30 , 95–98]. Here, we show that, after entering into the brain parenchyma, bloodborne IgG and FITC-labeled Aβ₄₂ introduced via tail vein injection preferentially associate with neurons, most notably pyramidal neurons in the cerebral cortex and large hilar neurons in the hippocampus, the same neurons that are IgG-immunopositive and have been shown to contain intracellular Aβ₄₂ deposits in human AD brains [30, 31]. Of the three treatment groups, mice receiving PT + Aβ₄₂ injections showed the highest number of cortical pyramidal neurons that were immunoreactive to IgG and Aβ₄₂. Cells with the largest deposits of Aβ₄₂ were most often positioned within a perivascular leak cloud or in the vicinity of a leaky blood vessel. In these cells, exogenous FITC-labeled Aβ₄₂ was primarily localized within discrete granules, presumably structures associated with the neuronal lysosomal compartment. Little or no bloodborne FITC-Aβ₄₂ entered the brains of mice with an intact BBB (saline controls), as has been reported previously [31]. The above findings suggest a causal relationship between chronic BBB breakdown, the resulting influx of soluble Aβ₄₂ and IgG into the brain tissue, the selective association and internalization of Aβ₄₂ in neurons and the pathogenesis of AD.

Evidence from a number of studies demonstrates that a substantial amount of Aβ₄₂ accumulates intracellularly in neurons of AD brains and in elderly mutant transgenic mice overexpressing AD-relevant genes [15 , 30–51]. Studies on AD transgenic mice have revealed that intraneuronal Aβ₄₂ accumulation invariably precedes the appearance of plaques and temporally coincides with loss of synapses, the appearance of initial cognitive deficits and, in a triple transgenic mouse model characterized by overexpression of mutant tau, AβPP, and presenilin (i.e., 3xTg-AD), the development of neurofibrillary tangles [15 , 99]. Collectively, this suggests that intraneuronal Aβ₄₂ accumulation is an early event in a disease process that eventually leads, either directly or indirectly, to neuronal and synaptic loss, the appearance of amyloid plaques and neurofibrillary tangles and associated neurological sequalae [17 , 100–102]. Based on this, it has been proposed that the gradual deposition of Aβ₄₂ within vulnerable neurons might progressively impair the ability of these cells to structurally and functionally support their extensive dendrite arbors and synapses, thus precipitating a gradual dendrite collapse that ultimately leads to deterioration of cognition and memory [30, 34]. Nevertheless, very little has been conclusively ascertained thus far concerning how and why Aβ₄₂ accumulates selectively in certain types of neurons, why aging predisposes these neurons to do so, and how this accumulation might induce its potential effects on neuron structure and function.

Possible relationship between the influx of brain-reactive antibodies and intraneuronal accumulation of Aβ₄₂

The present study shows that the same neuronal subtypes in mouse brain that exhibit intracellular deposits of Aβ₄₂ are also IgG-immunopositive, raising the possibility that the selective binding of IgG antibodies to the surfaces of these cells may somehow facilitate Aβ₄₂ internalization and accumulation [30 –32]. In a previous study, we tested the effects of human sera on the extent of neuronal IgG binding and intraneuronal deposition of soluble Aβ₄₂ in adult mouse neurons in organotypic brain slice cultures [30]. This study showed that binding of human serum IgG to the surfaces of mouse neurons was accompanied by a dramatic increase the rate and extent of Aβ₄₂ (both exogenous and endogenous) accumulation in neurons of the cerebral cortex and hippocampal region. Furthermore, replacement of human sera with specific antibodies targeting abundant neuronal surface proteins (e.g., the alpha7 nicotinic acetylcholine and glutamate R2 receptors) resulted in a comparable dramatic enhancement of exogenous Aβ₄₂ internalization and accumulation in mouse cortical and hippocampal neurons, compared to neurons treated with Aβ₄₂ alone [30, 103]. Taken together with the results of the present study, this suggests that increased BBB permeability allows bloodborne, brain-reactive IgG autoantibodies to access the brain interstitium and bind selectively to cognate targets on the surfaces of certain neuronal subtypes, which enhances intraneuronal deposition and accumulation of exogenous Aβ₄₂ peptide, presumably via the natural tendency of neurons to clear surface-bound antibodies via endocytosis [19 , 103].

Chronic, long-term BBB compromise and treatment with Aβ₄₂ peptide caused deficits in cognitive functioning

With respect to cognitive functioning, animals subjected to PT-induced, long-term BBB compromise and repeated injections of unlabeled or FITC-labeled Aβ₄₂ displayed a pattern of variable disruption of the acquisition of learned behaviors, a more consistent and preferential deficit in the capacity for long-term retention, and an increased susceptibility to interference in selective attention. We used a battery of behavioral and cognitive tests aimed at assessing animals’ learning (acquisition) and retention (long-term memory). Except for the odor discrimination task (where significant learning deficits were observed), experimental manipulations such as the PT-induced increase in BBB permeability and injection of Aβ₄₂ peptide had only a small and inconsistent effect on initial learning. However, mice in the PT-Aβ₄₂ group demonstrated significant deficits in long-term retention as revealed by the water maze and Lashley Maze tests. The specificity of the latter effect was particularly salient in light of intact acquisition on these same tasks.

In a test of selective attention that made no explicit demands (at the time of testing) on either learning or long-term retention, mice in the PT-Aβ₄₂ group expressed profound deficits. Selective attention evidenced a pattern of performance consistent with increased susceptibility to interference, manifested in specific impairment on later test trials, a segment most sensitive to accrual of interference. Since attentional abilities broadly influence cognitive processing [104, 105] this suggests that BBB breakdown and exogenous Aβ₄₂ may influence general cognitive abilities that extend beyond the tasks reported here.

The aggregate pattern of functional repercussions of experimental manipulation of BBB integrity and plasma Aβ₄₂ levels is particularly illuminating in view of implications for AD pathogenesis. Taken together, this profile is most consistent with a prodromal or emergent phase of AD [i.e., subtle cognitive impairment/mild cognitive impairment (MCI)], both with respect to absolute degree and distribution of impairment across domains of cognition or behavior. Individuals suffering from the amnestic variant of MCI, a subtype of MCI generally considered a transitional state for AD, typically display a specific profile that includes preferential deficits in long-term retention as compared to initial acquisition, coupled with variability in other domains of cognitive functioning. Behavioral disturbance is also common, including mild to moderate neuropsychiatric problems and mood changes such as anxiety, irritability, and apathy [106, 107]. Furthermore, the variable pattern of cognitive and behavioral deficits demonstrated here mirrors the unpredictable behavioral presentation and lack of consistent characterization of cognitive impairment associated with MCI. However, the most compelling parallels concern the specific profile of cognitive and behavioral impairment exhibited by animals treated with PT-Aβ₄₂, most prominently including a preferential deficit in long-term retention with respect to acquisition capacity, in addition to changes in selective attention. Remarkably, the pattern of results in the present model dovetails very closely with the staging observed in longitudinal studies assessing the progression of pathology in the 3xTg-AD model, a model which surpasses the present model in progression of pathology [36 , 108]. In this case, studies have demonstrated that the emergence of a specific and preferential deficit in long-term retention (i.e., with respect to acquisition as well as other cognitive functions) coincides temporally with the initial appearance of intracellular accumulation of Aβ₄₂, and both can be traced to initial phases of pathological progression, corresponding to early disease stages (i.e., MCI).

Limitations of the study

This study has some inherent limitations. First is the usage of PT for compromising cerebrovasculature and BBB. Though used extensively for this purpose, PT is a toxin that can lead to inflammatory changes. Secondly, this model does not show AD-associated terminal pathological changes such as amyloid plaques, neurofibrillary tangles, and significant neuronal loss, all of which may require longer study intervals. Another limitation concerns the age of the mice. Given the consistent and robust link between advanced age and development of AD (i.e., in sporadic, non-hereditary variants of AD), this is a core feature of AD that is likely to be important in attempts to replicate pathology and determine causal mechanisms. While the age of the mice used in the present model is sufficiently advanced to allow activation of some AD-related pathological processes, their relative youth may have attenuated key mechanisms implicated in AD pathogenesis and thus curbed emergence of more dramatic pathology. Such flaws are endemic to all mouse models that attempt to translate from rodent to human pathology. Lastly, these animals lack the larger arteries found in humans, blood vessels that are most associated with susceptibility to BBB dysfunction and ensuing vascular leak given their increased hydrostatic pressure. Nevertheless, despite these potential critiques, this model is comparable to other animal models in the reproduction of early pathological and behavioral alterations associated with AD, with the advantage of exhibiting pathogenic mechanisms in the absence of forced expression of various AD-relevant genes and their gene products.

Conclusions

Results presented here indicate that plasma derived Aβ₄₂ peptide and anti-neuronal autoantibodies can penetrate a chronically defective BBB, bind selectively to the surfaces of certain types of neurons and accumulate within these cells in the characteristic pattern of AD. These findings demonstrate that chronic BBB compromise and the ensuing influx of exogenous Aβ₄₂ and anti-neuronal autoantibodies from the blood over time can initiate or at least contribute to a cascade of neurological events and associated cognitive and behavioral changes that resemble those apparent in emerging AD. Taken in the context of research indicating widespread BBB deficiency in AD brains, these findings provide compelling evidence that the blood may serve as a chronic source of Aβ₄₂ peptides as well as neuron-binding autoantibodies in AD as they gain access to the brain tissue through a compromised BBB, and that the influx of soluble, exogenous Aβ₄₂ into the brain may be the origin of the intracellular Aβ₄₂ that accumulates within neurons early in AD pathogenesis.

AUTHOR CONTRIBUTIONS

Robert G Nagele (Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Writing – original draft; Writing – review & editing); Nimish K. Acharya (Formal analysis; Funding acquisition; Investigation; Methodology; Visualization; Writing – original draft; Writing – review & editing); Henya C. Grossman (Data curation); Peter M. Clifford (Data curation; Investigation; Methodology); Eli C. Levin (Data curation; Methodology); Kenneth R. Light (Data curation; Methodology); Hana Choi (Methodology); Randel L. Swanson (Formal analysis); Mary C. Kosciuk (Data curation; Methodology; Writing – review & editing); Venkat Venkataraman (Formal analysis; Investigation; Methodology); David J. Libon (Conceptualization; Writing – review & editing); Louis D. Matzel (Conceptualization; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Writing – review & editing).

Footnotes

ACKNOWLEDGMENTS

This manuscript includes a portion of the PhD thesis/dissertation work completed by Henya C Grossman (mentors, L Matzel and R Nagele) and Kenneth R Light (mentor, L Matzel), all of whom are co-authors.

The contents of this work do not represent the views of the Department of the Veterans Affairs or the US Government.

FUNDING

This work was supported by funds from the Osteopathic Heritage Foundation Endowment Intramural Funding Program and Rowan School of Osteopathic Medicine (to NKA and RGN), National Institute of Aging (NIA48387-06 to LDM), Alzheimer’s Association (to RGN) and Foundation of UMDNJ (RGN). RLS was supported, in part, by the US Department of Veterans Affairs Rehabilitation Research and Development Service under award number IK2 RX003651.

CONFLICT OF INTEREST

RGN and DJL are Editorial Board Members of this journal but were not involved in the peer-review process of this article nor had access to any information regarding its peer-review.

The authors have no other conflict of interest to report.

DATA AVAILABILITY

The data supporting the findings of this study are available within the article and/or its supplementary material.

The supplementary material is available in the electronic version of this article: .

References

Braak

, Braak

(1991) Neuropathological stageing ofAlzheimer-related changes. Acta Neuropathol 82, 239–259.

Braak

, Braak

(1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1, 213–216.

Blennow

, de Leon

, Zetterberg

(2006) Alzheimer’s disease. Lancet 368, 387–403.

Breijyeh

, Karaman

(2020) Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 25, 5789.

Scheltens

, Blennow

, Breteler

, de Strooper

, Frisoni

, Salloway

, Van der Flier

(2016) Alzheimer’s disease. Lancet 388, 505–517.

(2020) 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 16, 391–460.

Casey

, Antimisiaris

, O’Brien

(2010) Drugs for Alzheimer’s disease: Are they effective? P T 35, 208–211.

Mehta

, Jackson

, Paul

, Shi

, Sabbagh

(2017) Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs 26, 735–739.

Becker

, Greig

, Giacobini

(2008) Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J Alzheimers Dis 15, 303–325.

10.

Wilson

, Segawa

, Boyle

, Anagnos

, Hizel

, Bennett

(2012) The natural history of cognitive decline in Alzheimer’s disease. Psychol Aging 27, 1008–1017.

11.

, Larson

, Shofer

, Crane

, Gibbons

, McCormick

, Bowen

, Thompson

(2017) Cognitive trajectory changes over 20 years before dementia diagnosis: A large cohort study. J Am Geriatr Soc 65, 2627–2633.

12.

Jorm

, Masaki

, Petrovitch

, Ross

, White

(2005) Cognitive deficits 3 to 6 years before dementia onset in a population sample: The Honolulu-Asia aging study. J Am Geriatr Soc 53, 452–455.

13.

Emrani

, Lamar

, Price

, Wasserman

, Matusz

, Au

, Swenson

, Nagele

, Heilman

, Libon

(2020) Alzheimer’s/vascular spectrum dementia: Classification in addition to diagnosis. J Alzheimers Dis 73, 63–71.

14.

Morris

, Price

(2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci 17, 101–118.

15.

Oddo

, Caccamo

, Kitazawa

, Tseng

, LaFerla

(2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24, 1063–1070.

16.

Brier

, Gordon

, Friedrichsen

, McCarthy

, Stern

, Christensen

, Owen

, Aldea

, Su

, Hassenstab

, Cairns

, Holtzman

, Fagan

, Morris

, Benzinger

, Ances

(2016) Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease. , 338ra. Sci Transl Med 8, 366.

17.

Ossenkoppele

, Zwan

, Tolboom

, van Assema

, Adriaanse

, Kloet

, Boellaard

, Windhorst

, Barkhof

, Lammertsma

, Scheltens

, van der Flier

, van Berckel

(2012) Amyloid burden and metabolic function in early-onset Alzheimer’s disease: Parietal lobe involvement. Brain 135, 2115–2125.

18.

Klunk

, Engler

, Nordberg

, Wang

, Blomqvist

, Holt

, Bergstrom

, Savitcheva

, Huang

, Estrada

, Ausen

, Debnath

, Barletta

, Price

, Sandell

, Lopresti

, Wall

, Koivisto

, Antoni

, Mathis

, Langstrom

(2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55, 306–319.

19.

Thinakaran

, Koo

(2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283, 29615–29619.

20.

O’Brien

, Wong

(2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34, 185–204.

21.

De Simone

, Naldi

, Tedesco

, Milelli

, Bartolini

, Davani

, Widera

, Dallas

, Andrisano

(2019) Investigating in vitro amyloid peptide 1–42 aggregation: Impact of higher molecular weight stable adducts. ACS Omega 4, 12308–12318.

22.

Wilson

, Doms

, Lee

(1999) Intracellular APP processing and A beta production in Alzheimer disease. J Neuropathol Exp Neurol 58, 787–794.

23.

Koo

, Squazzo

(1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269, 17386–17389.

24.

Verdile

, Fuller

, Atwood

, Laws

, Gandy

, Martins

(2004) The role of beta amyloid in Alzheimer’s disease: Still a cause of everything or the only one who got caught? Pharmacol Res 50, 397–409.

25.

Alsunusi

, Kumosani

, Glabe

, Huwait

, Moselhy

(2022) In vitro study of the mechanism of intraneuronal beta-amyloid aggregation in Alzheimer’s disease. Arch Physiol Biochem 128, 732–739.

26.

Games

, Adams

, Alessandrini

, Barbour

, Berthelette

, Blackwell

, Carr

, Clemens

, Donaldson

, Gillespie

, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523–527.

27.

Citron

, Westaway

, Xia

, Carlson

, Diehl

, Levesque

, Johnson-Wood

, Lee

, Seubert

, Davis

, Kholodenko

, Motter

, Sherrington

, Perry

, Yao

, Strome

, Lieberburg

, Rommens

, Kim

, Schenk

, Fraser

, St George Hyslop

, Selkoe

(1997) Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67–72.

28.

Hsiao

, Chapman

, Nilsen

, Eckman

, Harigaya

, Younkin

, Yang

, Cole

(1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99–102.

29.

Johnson-Wood

, Lee

, Motter

, Hu

, Gordon

, Barbour

, Khan

, Gordon

, Tan

, Games

, Lieberburg

, Schenk

, Seubert

, McConlogue

(1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94, 1550–1555.

30.

Nagele

, Clifford

, Siu

, Levin

, Acharya

, Han

, Kosciuk

, Venkataraman

, Zavareh

, Zarrabi

, Kinsler

, Thaker

, Nagele

, Dash

, Wang

, Levitas

(2011) Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1–42) deposition. J Alzheimers Dis 25, 605–622.

31.

Clifford

, Zarrabi

, Siu

, Kinsler

, Kosciuk

, Venkataraman

, D’Andrea

, Dinsmore

, Nagele

(2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223–236.

32.

Goldwaser

, Acharya

, Wu

, Godsey

, Sarkar

, DeMarshall

, Kosciuk

, Nagele

(2020) Evidence that brain-reactive autoantibodies contribute to chronic neuronal internalization of exogenous amyloid-beta1–42 and key cell surface proteins during Alzheimer’s disease pathogenesis. J Alzheimers Dis 74, 345–361.

33.

Nagele

, D’Andrea

, Lee

, Venkataraman

, Wang

(2003) Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971, 197–209.

34.

Nagele

, D’Andrea

, Anderson

, Wang

(2002) Intracellular accumulation of beta-amyloid(1–42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110, 199–211.

35.

D’Andrea

, Nagele

, Wang

, Lee

(2002) Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer’s disease entorhinal cortex. Neurosci Lett 333, 163–166.

36.

Billings

, Oddo

, Green

, McGaugh

, LaFerla

(2005) Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 45, 675–688.

37.

Gomez-Ramos

, Asuncion Moran

(2007) Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis 11, 53–59.

38.

Takahashi

, Milner

, Li

, Nam

, Edgar

, Yamaguchi

, Beal

, Xu

, Greengard

, Gouras

(2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869–1879.

39.

Gouras

, Tsai

, Naslund

, Vincent

, Edgar

, Checler

, Greenfield

, Haroutunian

, Buxbaum

, Xu

, Greengard

, Relkin

(2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15–20.

40.

Oakley

, Cole

, Logan

, Maus

, Shao

, Craft

, Guillozet-Bongaarts

, Ohno

, Disterhoft

, Van Eldik

, Berry

, Vassar

(2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129–10140.

41.

Shie

, LeBoeuf

, Jin

(2003) Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport 14, 123–129.

42.

Wirths

, Multhaup

, Bayer

(2004) A modified beta-amyloid hypothesis: Intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. J Neurochem 91, 513–520.

43.

Wilson

, Abela

, Do Carmo

, Allard

, Marks

, Welikovitch

, Ducatenzeiler

, Chudasama

, Cuello

(2017) Intraneuronal amyloid beta accumulation disrupts hippocampal CRTC1-dependent gene expression and cognitive function in a rat model of Alzheimer disease. Cereb Cortex 27, 1501–1511.

44.

Welikovitch

, Do Carmo

, Magloczky

, Szocsics

, Loke

, Freund

, Cuello

(2018) Evidence of intraneuronal Abeta accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathol 136, 901–917.

45.

Kienlen-Campard

, Miolet

, Tasiaux

, Octave

(2002) Intracellular amyloid-beta 1–42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J Biol Chem 277, 15666–15670.

46.

Baker-Nigh

, Vahedi

, Davis

, Weintraub

, Bigio

, Klein

, Geula

(2015) Neuronal amyloid-beta accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain 138, 1722–1737.

47.

Moon

, Hong

, Nam

, Baik

, Song

, Kook

, Kim

, Lee

, Mook-Jung

(2012) Intracellular amyloid-beta accumulation in calcium-binding protein-deficient neurons leads to amyloid-beta plaque formation in animal model of Alzheimer’s disease. J Alzheimers Dis 29, 615–628.

48.

Christensen

, Bayer

, Wirths

(2010) Intracellular Ass triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer’s disease. Neurobiol Aging 31, 1153–1163.

49.

Wirths

, Bayer

(2012) Intraneuronal Abeta accumulation and neurodegeneration: Lessons from transgenic models. Life Sci 91, 1148–1152.

50.

Kobro-Flatmoen

, Hormann

, Gouras

(2023) Intracellular amyloid-beta in the normal rat brain and human subjects and its relevance for Alzheimer’s disease. J Alzheimers Dis 95, 719–733.

51.

LaFerla

, Green

, Oddo

(2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8, 499–509.

52.

Umeda

, Tomiyama

, Sakama

, Tanaka

, Lambert

, Klein

, Mori

(2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89, 1031–1042.

53.

Bayer

, Wirths

(2011) Intraneuronal Abeta as a trigger for neuron loss: Can this be translated into human pathology? Biochem Soc Trans 39, 857–861.

54.

Jeynes

, Provias

(2011) The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer’s disease. J Neurosci Res 89, 22–28.

55.

Hay

, Johnson

, Young

, Smith

, Stewart

(2015) Blood-brain barrier disruption is an early event that may persist for many years after traumatic brain injury in humans. J Neuropathol Exp Neurol 74, 1147–1157.

56.

Goodall

, Wang

, Simpson

, Baker

, Drew

, Heath

, Saffrey

, Romero

, Wharton

(2018) Age-associated changes in the blood-brain barrier: Comparative studies in human and mouse. Neuropathol Appl Neurobiol 44, 328–340.

57.

Goldwaser

, Acharya

, Sarkar

, Godsey

, Nagele

(2016) Breakdown of the cerebrovasculature and blood-brain barrier: A mechanistic link between diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis 54, 445–456.

58.

Erdo

, Denes

, de Lange

(2017) Age-associated physiological and pathological changes at the blood-brain barrier: A review. J Cereb Blood Flow Metab 37, 4–24.

59.

Alluri

, Shaji

, Davis

, Tharakan

(2018) A mouse controlled cortical impact model of traumatic brain injury for studying blood-brain barrier dysfunctions. Methods Mol Biol 1717, 37–52.

60.

Zlokovic

(2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178–201.

61.

Sweeney

, Montagne

, Sagare

, Nation

, Schneider

, Chui

, Harrington

, Pa

, Law

, Wang

DJJ

, Jacobs

, Doubal

, Ramirez

, Black

, Nedergaard

, Benveniste

, Dichgans

, Iadecola

, Love

, Bath

, Markus

, Salman

, Allan

, Quinn

, Kalaria

, Werring

, Carare

, Touyz

, Williams

SCR

, Moskowitz

, Katusic

, Lutz

, Lazarov

, Minshall

, Rehman

, Davis

, Wellington

, Gonzalez

, Yuan

, Lockhart

, Hughes

, Chen

CLH

, Sachdev

, O’Brien

, Skoog

, Pantoni

, Gustafson

, Biessels

, Wallin

, Smith

, Mok

, Wong

, Passmore

, Barkof

, Muller

, Breteler

MMB

, Roman

, Hamel

, Seshadri

, Gottesman

, van Buchem

, Arvanitakis

, Schneider

, Drewes

, Hachinski

, Finch

, Toga

, Wardlaw

, Zlokovic

(2019) Vascular dysfunction-The disregarded partner of Alzheimer’s disease. Alzheimers Dement 15, 158–167.

62.

Montagne

, Barnes

, Sweeney

, Halliday

, Sagare

, Zhao

, Toga

, Jacobs

, Liu

, Amezcua

, Harrington

, Chui

, Law

, Zlokovic

(2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302.

63.

Kalaria

(2016) Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathol 131, 659–685.

64.

Toledo

, Arnold

, Raible

, Brettschneider

, Xie

, Grossman

, Monsell

, Kukull

, Trojanowski

(2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 136, 2697–2706.

65.

Andreasen

, Blennow

(2002) Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides 23, 1205–1214.

66.

Feinkohl

, Schipke

, Kruppa

, Menne

, Winterer

, Pischon

, Peters

(2020) Plasma amyloid concentration in Alzheimer’s disease: Performance of a high-throughput amyloid assay in distinguishing Alzheimer’s disease cases from controls. J Alzheimers Dis 74, 1285–1294.

67.

Tapiola

, Alafuzoff

, Herukka

, Parkkinen

, Hartikainen

, Soininen

, Pirttila

(2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382–389.

68.

Tapiola

, Pirttila

, Mikkonen

, Mehta

, Alafuzoff

, Koivisto

, Soininen

(2000) Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci Lett 280, 119–122.

69.

Lewczuk

, Esselmann

, Otto

, Maler

, Henkel

, Eikenberg

, Antz

, Krause

, Reulbach

, Kornhuber

, Wiltfang

(2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25, 273–281.

70.

, Zhao

, Dong

(2022) A Review of application of Abeta42/40 ratio in diagnosis and prognosis of Alzheimer’s disease. J Alzheimers Dis 90, 495–512.

71.

Levin

, Acharya

, Han

, Zavareh

, Sedeyn

, Venkataraman

, Nagele

(2010) Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 1345, 221–232.

72.

Acharya

, Levin

, Clifford

, Han

, Tourtellotte

, Chamberlain

, Pollaro

, Coretti

, Kosciuk

, Nagele

, Demarshall

, Freeman

, Shi

, Guan

, Macphee

, Wilensky

, Nagele

(2013) Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: Beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis 35, 179–198.

73.

Acharya

, Goldwaser

, Forsberg

, Godsey

, Johnson

, Sarkar

, DeMarshall

, Kosciuk

, Dash

, Hale

, Leonard

, Appelt

, Nagele

(2015) Sevoflurane and Isoflurane induce structural changes in brain vascular endothelial cells and increase blood-brain barrier permeability: Possible link to postoperative delirium and cognitive decline. Brain Res 1620, 29–41.

74.

Zagorski

, Yang

, Shao

, Ma

, Zeng

, Hong

(1999) Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol 309, 189–204.

75.

Matzel

, Han

, Grossman

, Karnik

, Patel

, Scott

, Specht

, Gandhi

(2003) Individual differences in the expression of a “general” learning ability in mice. J Neurosci 23, 6423–6433.

76.

Matzel

, Townsend

, Grossman

, Han

, Hale

, Zappulla

, Light

, Kolata

(2006) Exploration in outbred mice covaries with general learning abilities irrespective of stress reactivity, emotionality, and physical attributes. Neurobiol Learn Mem 86, 228–240.

77.

Kolata

, Light

, Grossman

, Hale

, Matzel

(2007) Selective attention is a primary determinant of the relationship between working memory and general learning ability in outbred mice. Learn Mem 14, 22–28.

78.

Webster

, Bachstetter

, Nelson

, Schmitt

, Van Eldik

(2014) Using mice to model Alzheimer’s dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5, 88.

79.

Puzzo

, Lee

, Palmeri

, Calabrese

, Arancio

(2014) Behavioral assays with mouse models of Alzheimer’s disease: Practical considerations and guidelines. Biochem Pharmacol 88, 450–467.

80.

Morris

RGM

(1981) Spatial localization does not require the presence of local cues. Learn Motiv 12, 239–260.

81.

Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18, 643–662.

82.

Light

, Kolata

, Wass

, Denman-Brice

, Zagalsky

, Matzel

(2010) Working memory training promotes general cognitive abilities in genetically heterogeneous mice. Curr Biol 20, 777–782.

83.

D’Andrea

, Nagele

(2010) Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer’s disease pathogenesis. Biotech Histochem 85, 133–147.

84.

Acharya

, Nagele

, Han

, Coretti

, DeMarshall

, Kosciuk

, Boulos

, Nagele

(2012) Neuronal PAD4 expression and protein citrullination: Possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun 38, 369–380.

85.

Zipser

, Johanson

, Gonzalez

, Berzin

, Tavares

, Hulette

, Vitek

, Hovanesian

, Stopa

(2007) Microvascular injury and blood-brain barrier leakage in Alzheimer’s disease. Neurobiol Aging 28, 977–986.

86.

Yamazaki

, Kanekiyo

(2017) Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. Int J Mol Sci 18, 1965.

87.

Verheggen

ICM

, de Jong

JJA

, van Boxtel

MPJ

, Gronenschild

, Palm

, Postma

, Jansen

JFA

, Verhey

FRJ

, Backes

(2020) Increase in blood-brain barrier leakage in healthy, older adults. Geroscience 42, 1183–1193.

88.

van de Haar

, Burgmans

, Jansen

, van Osch

, van Buchem

, Muller

, Hofman

, Verhey

, Backes

(2016) Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology 281, 527–535.

89.

Sweeney

, Zhao

, Montagne

, Nelson

, Zlokovic

(2019) Blood-brain barrier: From physiology to disease and back. Physiol Rev 99, 21–78.

90.

Sweeney

, Kisler

, Montagne

, Toga

, Zlokovic

(2018) The role of brain vasculature in neurodegenerative disorders. Nat Neurosci 21, 1318–1331.

91.

Nation

, Sweeney

, Montagne

, Sagare

, D’Orazio

, Pachicano

, Sepehrband

, Nelson

, Buennagel

, Harrington

, Benzinger

TLS

, Fagan

, Ringman

, Schneider

, Morris

, Chui

, Law

, Toga

, Zlokovic

(2019) Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25, 270–276.

92.

Mooradian

(1988) Effect of aging on the blood-brain barrier. Neurobiol Aging 9, 31–39.

93.

Kalaria

(1999) The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci 893, 113–125.

94.

, Pelech

, Zhang

, Bond

, Spach

, Noubade

, Blankenhorn

, Teuscher

(2008) Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. J Neurosci Res 86, 2624–2640.

95.

Zlokovic

, Ghiso

, Mackic

, McComb

, Weiss

, Frangione

(1993) Blood-brain barrier transport of circulating Alzheimer’s amyloid beta. Biochem Biophys Res Commun 197, 1034–1040.

96.

Kandimalla

, Curran

, Holasek

, Gilles

, Wengenack

, Poduslo

(2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer’s disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313, 1370–1378.

97.

Poduslo

, Curran

, Sanyal

, Selkoe

(1999) Receptor-mediated transport of human amyloid beta-protein 1–40 and 1–42 at the blood-brain barrier. Neurobiol Dis 6, 190–199.

98.

Deane

, Zlokovic

(2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 4, 191–197.

99.

Oddo

, Caccamo

, Tran

, Lambert

, Glabe

, Klein

, LaFerla

(2006) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281, 1599–1604.

100.

Sosna

, Philipp

, Albay

3rd , Reyes-Ruiz

, Baglietto-Vargas

, LaFerla

, Glabe

(2018) Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol Neurodegener 13, 11.

101.

Takahashi

, Capetillo-Zarate

, Lin

, Milner

, Gouras

(2013) Accumulation of intraneuronal beta-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses. PLoS One 8, e51965.

102.

Trojanowski

, Hampel

(2011) Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol 95, 491–495.

103.

Kurup

, Zhang

, Xu

, Venkitaramani

, Haroutunian

, Greengard

, Nairn

, Lombroso

(2010) Abeta-mediated NMDA receptor endocytosis in Alzheimer’s disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 30, 5948–5957.

104.

Burgoyne

, Mashburn

, Tsukahara

, Engle

(2022) Attention control and process overlap theory: Searching for cognitive processes underpinning the positive manifold. Intelligence 91, 101629.

105.

Sauce

, Wass

, Smith

, Kwan

, Matzel

(2014) The external-internal loop of interference: Two types of attention and their influence on the learning abilities of mice. Neurobiol Learn Mem 116, 181–192.

106.

Dion

, Arias

, Amini

, Davis

, Penney

, Libon

, Price

(2020) Cognitive correlates of digital clock drawing metrics in older adults with and without mild cognitive impairment. J Alzheimers Dis 75, 73–83.

107.

Hwang

, Masterman

, Ortiz

, Fairbanks

, Cummings

(2004) Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 18, 17–21.

108.

Golde

, Janus

(2005) Homing in on intracellular Abeta? Neuron 45, 639–642.

A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta 1–42 Peptide in the Brain and Leads to Alzheimer’s Disease-Relevant Cognitive Changes in a Mouse Model

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

INTRODUCTION

MATERIALS AND METHODS

Animals

Preparation of Aβ42 peptides and PT

Animal treatments

Behavioral training and testing procedures

Odor discrimination and choice

One-trial passive avoidance

Spatial Water Maze

Lashley III Maze

Selective attention/attentional disengagement

Tissue preparation for neuropathological studies

Brightfield immunohistochemistry

Fluorescent imaging

Counting the number of IgG or Aβ42 positive neurons

Statistical analyses

RESULTS

Odor discrimination

Passive avoidance: post/pre-latency(s)

Spatial Water Maze

Lashley III Maze

Selective attention

Repetitive Pertussis toxin (PT) treatments facilitate chronic compromise of BBB integrity and leak of plasma components, including IgG antibodies, into the cerebral cortex

Chronically increased BBB permeability allows IgG antibodies to enter the brain parenchyma and bind selectively to neurons, especially pyramidal cells in the cerebral cortex

Chronic BBB compromise allows bloodborne Aβ42 to enter the brain parenchyma and accumulate within neurons in the cerebral cortex

BBB compromise increases the density of Aβ42-positive neurons

Accumulation of bloodborne Aβ42 within hippocampal hilar neurons

DISCUSSION

BBB compromise and AD

Bloodborne IgG and Aβ42 preferentially associate with pyramidal neurons

Possible relationship between the influx of brain-reactive antibodies and intraneuronal accumulation of Aβ42

Chronic, long-term BBB compromise and treatment with Aβ42 peptide caused deficits in cognitive functioning

Limitations of the study

Conclusions

AUTHOR CONTRIBUTIONS

Footnotes

ACKNOWLEDGMENTS

FUNDING

CONFLICT OF INTEREST

DATA AVAILABILITY

References

Preparation of Aβ₄₂ peptides and PT

Counting the number of IgG or Aβ₄₂ positive neurons

Chronic BBB compromise allows bloodborne Aβ₄₂ to enter the brain parenchyma and accumulate within neurons in the cerebral cortex

BBB compromise increases the density of Aβ₄₂-positive neurons

Accumulation of bloodborne Aβ₄₂ within hippocampal hilar neurons

Bloodborne IgG and Aβ₄₂ preferentially associate with pyramidal neurons

Possible relationship between the influx of brain-reactive antibodies and intraneuronal accumulation of Aβ₄₂

Chronic, long-term BBB compromise and treatment with Aβ₄₂ peptide caused deficits in cognitive functioning